| abstract |
The invention provides methods of diagnosing multiple sclerosis (MS) patients, including methods of identifying multiple sclerosis patients who are at increased risk of developing a secondary autoimmune disease following lymphocyte depletion, caused, e.g., by treatment with an anti-CD52 antibody. Also embraced are methods of selecting treatment regimens for MS patients, and reagents useful in the above methods. |